Back

SGLT2 inhibitors in HFpEF - Light at the end of the tunnel.

29 August 2022 (12:45 - 13:00)
Organised by:
Congress Presentation Part of: SGLT-2 inhibitors - Another piece of the puzzle in heart failure Heart Failure with Preserved Ejection Fraction (HFpEF) Open Access ESC Congress 2022

About the speaker

Photo
Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
SGLT2 inhibitors across the spectrum of heart failure.
Professor J. McMurray (Glasgow, GB)
Slides Video
Presentation thumbnail
Practical considerations for treating HF with mildly reduced and preserved EF.
Professor C. Lam (Singapore, SG)
Slides Video
Presentation thumbnail
Implementing best practices across the spectrum of heart failure.
Doctor M. Vaduganathan (Boston, US)
Slides Video
Presentation thumbnail
Summary.
Slides Video
Presentation thumbnail
Discussion.
Video

Access the full session

Session thumbnail
SGLT-2 inhibitors - Another piece of the puzzle in heart failure
Video

The Event

Event poster

ESC Congress 2022

29 August 2022 12:45 CET
You may be interested in
thumbnail
Congress Presentation
Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial
thumbnail
Congress Presentation
Effect of dapagliflozin on outpatient worsening heart failure in patients with mildly reduced or preserved ejection fraction: the DELIVER trial
thumbnail
Congress Presentation
Influence of achieved LVEF on efficacy of dapagliflozin in patients with heart failure with improved ejection fraction: the DELIVER trial